SOURCE-LINKED STUDY SUMMARY
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Abstract summarizedQuality not appraised
- What was studied
- Double-blind phase 2 trial comparing weekly LY3298176, now known as tirzepatide, at four doses with dulaglutide or placebo.
- Who / model studied
- The study randomized 318 adults with inadequately controlled type 2 diabetes; 316 received treatment, and 258 completed 26 weeks of treatment.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- HbA1c reductions were dose-dependent, reaching -1·94% with 15 mg versus -0·06% with placebo and -1·21% with dulaglutide. Weight change ranged from -0·9 kg to -11·3 kg. Gastrointestinal events increased with dose; no severe hypoglycaemia was reported.
- Limitations & context
- This 26-week phase 2 trial had incomplete treatment completion and was funded by Eli Lilly. It does not establish longer-term effectiveness or safety.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s0140-6736(18)32260-8